Antithrombotic efficacy of an oral thrombin inhibitor (TI) in a conscious rat model of deep venous thrombosis (DVT) with and without aspirin (ASA).

被引：0
|
作者：
Wilson, A [1 ]
Smith, T [1 ]
Shuman, RT [1 ]
Kurz, KD [1 ]
机构：
[1] LILLY RES LABS,INDIANAPOLIS,IN
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：350 / 350
页数：1
相关论文
共 33 条
  • [21] Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis
    Heran, C
    Morgan, S
    Kasiewski, C
    Bostwick, J
    Bentley, R
    Klein, S
    Chu, V
    Brown, K
    Colussi, D
    Czekaj, M
    Perrone, M
    Leadley, R
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 389 (2-3) : 201 - 207
  • [22] Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis
    Sarich, TC
    Osende, JI
    Eriksson, UG
    Fager, GB
    Eriksson-Lepkowska, M
    Ohlsson, L
    Carlsson, S
    Wåhlander, K
    Gustafsson, D
    Badimon, JJ
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (05) : 999 - 1004
  • [23] Simultaneous assessment of arterial and venous thrombin inhibitor efficacy in a rabbit model of FeCl3-induced thrombosis.
    Lyle, EM
    Brady, SF
    Lewis, SD
    Nutt, RF
    Lynch, JJ
    FASEB JOURNAL, 1996, 10 (03): : 2502 - 2502
  • [24] ASSESSMENT OF THE ANTICOAGULANT AND ANTITHROMBOTIC EFFICACY OF THE THROMBIN INHIBITOR, BOC-D-PHE-PRO-ARGINAL, IN A CANINE MODEL OF CORONARY-THROMBOSIS
    JACKSON, CV
    FRANK, JD
    CROWE, VG
    CRAFT, TJ
    SMITH, GF
    ARTERIOSCLEROSIS, 1990, 10 (05): : A922 - A923
  • [25] Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered
    Hiebert, Linda M.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2017, 22 (03) : 264 - 272
  • [26] Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
    Buller, H.
    Deitchman, D.
    Prins, M.
    Segers, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (08) : 1313 - 1318
  • [27] ANTICOAGULANT AND ANTITHROMBOTIC EFFICACY OF THE THROMBIN INHIBITOR, METHYL-D-PHE-PRO-ARGINAL (GKYI-14766), IN A CANINE MODEL OF CORONARY-THROMBOSIS
    CROWE, V
    FRANK, J
    WILSON, H
    COFFMAN, B
    SMITH, G
    JACKSON, V
    FASEB JOURNAL, 1991, 5 (04): : A520 - A520
  • [28] Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism:: The THRIVE treatment study.
    Francis, CW
    Ginsberg, JS
    Berkowitz, SD
    Bounameaux, H
    Davidson, BL
    Eriksson, H
    Fiessinger, JN
    Huisman, MV
    Lundström, T
    Nyström, P
    BLOOD, 2003, 102 (11) : 6A - 6A
  • [29] THRIVE I:: Efficacy and tolerability of the novel, oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis.
    Schulman, S
    Wåhlander, K
    Gustafsson, D
    Welin, L
    Frison, L
    Eriksson, H
    BLOOD, 2001, 98 (11) : 447A - 448A
  • [30] Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism:: the THRIVE Treatment Study
    Wimperis, J
    Fiessinger, JN
    Huisman, MV
    Davidson, BL
    Bounameaux, H
    Francis, CW
    Eriksson, I
    Lundström, T
    Berkowitz, SD
    Nyström, P
    Ginsberg, JS
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 : 66 - 66
1234